PSMB9 and nasopharyngeal carcinoma: In a pilot study of 29 subjects, intradermal injection of LMP2-DCs using an adenovirus expressing LMP2 (Ad-LMP2) achieved a five-year survival rate of 94.4% in NPC responders, indicating enhanced responses to LMP2 peptide pools [141].